Basic Sildalis Information

• INN (International Nonproprietary Name): Sildalis does not have an official INN; it is a combination tablet containing sildenafil citrate (INN: sildenafil) and tadalafil (INN: tadalafil).
• Brand Names Available In United States: Sildalis is marketed as an internet-sold combination drug and is not distributed through registered U.S. pharmacy supply chains; its packaging is most commonly seen online rather than in licensed pharmacies.
• ATC Code: Sildenafil — G04BE03; Tadalafil — G04BE08.
• Forms & Dosages: Tablet. Typical marketed strength is 100 mg sildenafil + 20 mg tadalafil in blister packs (6–20 tablets).
• Manufacturers In United States: Not produced by major original manufacturers in the U.S.; manufacturing is typically attributed to Indian generic companies or direct-to-web suppliers.
• Registration Status In United States: Not registered with major regulatory agencies as a fixed sildenafil+tadalafil combination product.
• OTC / Rx Classification: Prescription-only in jurisdictions that regulate sildenafil or tadalafil; commonly sold without prescription via some online retailers outside regulated supply chains.

Key Findings From Recent Trials

Major 2022–2026 Studies

Patients and prescribers often ask whether there is high-quality trial evidence supporting combination sildenafil plus tadalafil tablets.

No randomized, registry-grade trials have evaluated the fixed-tablet sildenafil+tadalafil product Sildalis in major regulatory databases.

Therefore the strongest evidence comes from high-quality randomized controlled trials of sildenafil and tadalafil monotherapy published through 2022–2024 and from observational reports of combination use on online markets.

Contemporary RCTs show consistent efficacy for sildenafil as a short-acting PDE5 inhibitor for on-demand erectile dysfunction.

Tadalafil RCTs demonstrate durable efficacy extending up to 36 hours and often improve spontaneity of sexual activity compared with on-demand-only agents.

Main Outcomes

Sildenafil delivers a reliable on-demand response with onset typically around 30–60 minutes, improving erectile function scores in RCTs.

Tadalafil offers a longer therapeutic window with similar efficacy by standard outcomes and is available as both on-demand and low-dose daily formulations.

Extrapolating from monotherapy data, a combined 100 mg sildenafil + 20 mg tadalafil tablet could theoretically offer both rapid onset and an extended window.

However, no pharmacokinetic or safety randomized controlled trial confirms additive benefit, altered metabolism, or improved clinical outcomes for the fixed combination.

Clinical certainty is therefore limited to mechanistic reasoning and anecdotal reports rather than combination-specific trial evidence.

Safety Observations

Pooled safety data for PDE5 inhibitors show dose-related adverse effects including headache, facial flushing, nasal congestion, and visual disturbances.

Sildenafil is associated more with transient visual changes and color tinge, while tadalafil often causes back and muscle pain in some patients.

Combination use raises theoretical risks of additive vasodilation and greater incidence or severity of these adverse effects.

Regulatory concerns include absence of formal approval for combination products and higher patient risk when sold without prescription or outside regulated supply chains.

Clinical Mechanism Of Action

Layman’s Explanation

Patients usually want a simple answer: how do these pills work?

Both sildenafil and tadalafil relax the small muscles in penile blood vessels so more blood can fill the penis during sexual stimulation.

Sildenafil typically works faster but wears off sooner, while tadalafil remains active much longer, allowing a broader window for intimacy.

Sildalis combines both agents in one tablet (marketed as 100 mg sildenafil + 20 mg tadalafil) to try to deliver immediate effect plus longer duration.

Scientific Breakdown

Both drugs are selective inhibitors of phosphodiesterase type 5 (PDE5) in the corpus cavernosum, preventing breakdown of cyclic GMP.

Increased cyclic GMP enhances nitric oxide–mediated smooth muscle relaxation, promoting penile blood flow during sexual arousal.

Pharmacokinetically, sildenafil reaches peak plasma concentration at about 30–120 minutes with a half-life of roughly 3–5 hours.

Tadalafil reaches peak levels at about 2 hours and has a half-life near 17.5 hours, supporting activity up to 36 hours after dosing.

PDE5 Inhibition — Sildenafil Vs Tadalafil

Sildenafil’s advantages are predictable on-demand effect and well-characterized onset for erectile dysfunction treatment.

Tadalafil’s long half-life allows more spontaneous sexual activity and the option of daily low-dose therapy for continuous coverage.

Both agents are PDE5 inhibitors and share the same general mechanism, but their different pharmacokinetic profiles inform clinical choice between Viagra-like rapid onset and Cialis-like prolonged effect.

Potential Combined Pharmacodynamics

Combining sildenafil and tadalafil raises theoretical concerns about additive systemic vasodilation and a higher risk of hypotension.

Both drugs are metabolized primarily by CYP3A4, so co-administration may create competitive metabolism, although no formal PK studies on Sildalis exist.

Clinicians must therefore assume combined exposure approximates the sum of individual exposures and monitor for hypotension, visual disturbances, and myalgias.

Given the lack of controlled combination trials, decisions about combination use should be conservative and individualized.

Scope Of Approved & Off-Label Use

United States Approvals

Many patients ask whether Sildalis is an FDA‑approved product in the United States.

It is not registered with major drug agencies as a fixed sildenafil+tadalafil combination product.

Sildenafil and tadalafil individually are FDA‑approved for erectile dysfunction, and tadalafil also has approvals for benign prostatic hyperplasia and pulmonary arterial hypertension in specific formulations.

Sildalis is primarily marketed online and through unofficial distributors rather than established, regulated U.S. pharmacy supply chains.

Notable Off-Label Trends

Online vendors and some patients seek combined formulations to achieve “enhanced potency” or a wider time window.

Clinician reports and pharmacovigilance signals warn about unsupervised use, inconsistent manufacturing quality, and bypassing prescription safeguards.

Indian generic manufacturers and direct-to-web suppliers are commonly cited producers of Sildalis-style tablets sold internationally.

Off-label experimental use sometimes occurs in refractory cases, but this practice lacks safety and efficacy data specific to the combination product.

Dosage Strategy

General Dosing

Marketed Sildalis tablets typically contain 100 mg sildenafil plus 20 mg tadalafil and are labeled for single on-demand use 30–60 minutes before sexual activity.

Product labeling commonly advises not to exceed one tablet every 24 hours.

Because that fixed dose pairs a high sildenafil dose with a full tadalafil dose, many clinicians would consider this exposure high for many patients.

No dose-finding or randomized trials exist to guide lowering or titration of this specific fixed combination.

Condition-Specific Dosing

Standard monotherapy options still guide most clinical practice: sildenafil 25–100 mg on-demand and tadalafil 5–20 mg on-demand or 2.5–5 mg daily for continuous coverage.

The marketed Sildalis 100/20 mg combination effectively pairs a high on-demand sildenafil dose with a full tadalafil dose and therefore may not be appropriate for elderly patients or those with hepatic or renal impairment.

Children are not approved for this therapy, and dose reductions are standard practice with impaired clearance for individual agents.

When a patient requests combination use, clinicians should discuss the absence of combination-specific guidance and favor individualized prescribing of single agents where possible.

Safety Protocols

Contraindications

Absolute contraindications reflect the individual PDE5 inhibitor labels.

Do not use Sildalis in patients with known allergy to sildenafil, tadalafil, or any excipients.

Concomitant use with nitrates or nitric oxide donors is an absolute contraindication because of risk of life-threatening hypotension.

Use with riociguat for pulmonary hypertension is also contraindicated.

Severe cardiovascular disease that precludes sexual activity is another absolute exclusion.

Adverse Effects

Common mild-to-moderate side effects include headache, flushing, nasal congestion, dizziness, and dyspepsia.

Sildenafil is especially associated with transient visual disturbances such as a bluish tinge or blurred vision.

Tadalafil has a higher association with muscle and back pain in some patients.

Combined exposure may increase the frequency or intensity of these adverse events.

Emergency risks include severe hypotension, syncope, and priapism; seek immediate care for an erection lasting longer than four hours.

Interaction Mapping

Food Interactions

High‑fat meals can delay absorption of sildenafil and slow onset of action.

Tadalafil absorption is less affected by food.

When taking a combined product, a fatty meal may blunt the rapid onset expected from the sildenafil component, though tadalafil’s long duration will remain.

For faster onset, take the tablet on an empty or light stomach 30–60 minutes before activity.

Drug Combinations To Avoid

Never combine any PDE5 inhibitor with nitrates because of the risk of profound hypotension.

Riociguat is also contraindicated with PDE5 inhibitors.

Use caution with alpha‑blockers, antihypertensives, and agents that strongly inhibit CYP3A4, which can raise plasma levels of sildenafil and tadalafil.

Avoid grapefruit and certain herbal products that alter CYP3A4 activity when using PDE5 inhibitors.

Because no interaction trials exist for the fixed combination, assume additive pharmacodynamic effects and monitor closely when necessary.

Patient Experience Analysis

Survey Data

There are no peer‑reviewed, large surveys specifically for Sildalis because it is not a registered combination product.

Published patient-reported outcomes for PDE5 inhibitors suggest high satisfaction when efficacy and tolerability align with patient expectations.

Surveys commonly show tadalafil scores higher for spontaneity and patient satisfaction, and sildenafil scores higher for predictable on-demand onset.

Non‑representative online questionnaires of combined-product users report perceived longer duration and potency, but such data are biased and unverified.

Forum Trends

Online forums and seller testimonials often praise the “double action” convenience of the combination tablet.

Common consumer complaints include variable tablet authenticity, inconsistent packaging, and adverse events when taken with contraindicated medications.

Clinicians warn that forum reports are anecdotal and that counterfeit supply from nonregulated sources is a real risk.

Patients should be counseled to seek licensed pharmacy options and medical review rather than relying on unverified online testimonials.

Distribution & Pricing Landscape

Distribution

Sildalis is primarily sold through online pharmacies and unofficial distributors rather than registered local pharmacies.

Pill packaging commonly shows red, oval tablets in blister packs with English or Russian labeling.

Major branded manufacturers like Pfizer and Eli Lilly do not produce Sildalis; manufacturers are usually smaller Indian generic firms or direct-to-web suppliers.

In Western markets, Sildalis is typically not available through official supply chains and therefore lacks the regulatory traceability of approved monotherapies.

Pricing

Online prices vary widely and are often lower than branded Viagra or Cialis, which contributes to consumer demand.

Lower price points, however, often correlate with increased regulatory and quality risk, including dose inaccuracy or contamination.

Purchasing without a prescription also bypasses pharmacist screening for contraindications and interactions.

In our online pharmacy, sildalis is available without a prescription, with discreet delivery to United States in 5-14 days.

Alternative Options

Comparison Table

If you are considering alternatives, licensed monotherapy remains the standard of care.

Viagra (sildenafil), Cialis (tadalafil), and Levitra (vardenafil) each have robust clinical trial evidence and regulatory oversight.

Options include on-demand sildenafil 25–100 mg, on-demand tadalafil 5–20 mg, or daily tadalafil 2.5–5 mg for continuous coverage.

These alternatives permit dose titration, monitoring, and established pharmacovigilance unlike unregistered fixed combinations.

Pros And Cons

Pros claimed for Sildalis include single-tablet convenience and combined onset-plus-window advantages, but these remain marketing claims without formal PK or RCT support.

Cons include lack of registration, unknown manufacturing quality, potential for additive adverse effects, and serious contraindications that are not mitigated by combined labeling.

Clinically, licensed monotherapy provides predictable dosing, documented safety profiles, and pharmacist oversight.

Regulatory Status

Regulatory Snapshot

Sildalis is not registered with the FDA, EMA, MHRA, or similar agencies as a fixed sildenafil+tadalafil combination product.

No public regulatory record exists for an approved combination of these two active ingredients in a single tablet.

Individual active ingredients retain established ATC codes, but regulators do not recognize a combined fixed-dose product.

Implications

Non‑registration means there has been no centralized review of manufacturing, bioequivalence, or combination-specific safety and efficacy.

Products sold online can evade prescription safeguards in some jurisdictions, though sildenafil and tadalafil remain prescription-only where regulated.

Clinicians should be cautious when patients present with unregistered combinations and document product source and batch if possible for pharmacovigilance.

Consolidated FAQ

Safety And Efficacy

Q: Is Sildalis an approved medication?

A: No—Sildalis is a non‑registered combination tablet; sildenafil and tadalafil individually are approved, but the fixed combination is not registered with major agencies.

Q: Is it safe to take Sildalis with nitrates?

A: No—concomitant nitrates are an absolute contraindication due to the risk of severe hypotension.

Q: How should it be dosed?

A: Marketed dosing is one tablet (100 mg sildenafil + 20 mg tadalafil) taken 30–60 minutes before activity and not more than once per 24 hours, but clinicians caution this is a high exposure and recommend medical supervision.

Purchasing And Authenticity

Q: Can I buy Sildalis without a prescription?

A: Many online sellers offer it without a prescription, but in regulated jurisdictions sildenafil and tadalafil are prescription-only; buying without supervision is risky.

Guidance: confirm product authenticity, consult a clinician before use, and prefer licensed monotherapy options where possible.

Report adverse events to your healthcare provider and local pharmacovigilance authorities.

Visual Guide

Tablet Identification

Sildalis is commonly packaged as red, oval tablets in blister packs and is often labeled in English or Russian.

Typical marketed strength on packaging is 100 mg sildenafil + 20 mg tadalafil per tablet.

Consistent pill shape, clear engraving, batch number, expiration date, and manufacturer contact are positive visual cues but are not absolute proof of authenticity.

Packaging Cues And Red Flags

Missing or inconsistent labeling, foreign-language-only inserts without regulatory markings, or unusually low prices are red flags for counterfeit or unregistered products.

Anonymous online storefronts and lack of prescription requirements suggest you should avoid ordering and instead seek licensed options through a pharmacist or prescriber.

Storage & Transport

Storage Guidance

Store Sildalis below 30°C (86°F), away from moisture and direct sunlight.

Keep the product out of the reach of children and follow local disposal guidelines for unused medication.

Transport Considerations

Online shipments may travel through varied climates; while cold-chain transport is not required, avoid extreme heat which can degrade active ingredients.

Prefer reputable sellers with traceable origin and secure packaging, and carry medication in original packaging with a prescription or physician note when traveling if required by local law.

Guidelines For Proper Use

Pre-Use Assessment

Before prescribing or using a combination tablet, screen for cardiovascular risk, concomitant nitrate therapy, riociguat use, liver or kidney impairment, and CYP3A4 inhibitor co-medications.

Given the fixed 100/20 mg composition, many patients will require lower doses or alternative regimens.

Discuss benefits versus risks and document informed consent if a patient chooses to use an unregistered combination despite medical advice.

Monitoring And When To Seek Help

Counsel patients on expected side effects such as headache, flushing, indigestion, temporary visual changes, and muscle pain.

Advise immediate medical attention for chest pain, syncope, severe hypotension, sudden vision or hearing loss, or priapism lasting more than four hours.

Document product source and batch number where possible to facilitate adverse‑event reporting and pharmacovigilance.

Delivery Across United States